See more : Inpex Corporation (IPXHY) Income Statement Analysis – Financial Results
Complete financial analysis of Global Partners LP (GLP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Global Partners LP, a leading company in the Oil & Gas Midstream industry within the Energy sector.
- Dr. Hönle AG (HNL.DE) Income Statement Analysis – Financial Results
- Eiken Industries Co.,Ltd. (7265.T) Income Statement Analysis – Financial Results
- Snap-on Incorporated (SNA) Income Statement Analysis – Financial Results
- Signal Hill Acquisition Corp. (SGHLW) Income Statement Analysis – Financial Results
- White River Energy Corp. (WTRV) Income Statement Analysis – Financial Results
Global Partners LP (GLP)
About Global Partners LP
Global Partners LP engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, and propane to wholesalers, retailers, and commercial customers in the New England states, Mid-Atlantic region, and New York. The company is also involved in the transportation of petroleum products and renewable fuels through rail from the mid-continent region of the United States and Canada. Its Wholesale segment sells home heating oil, branded and unbranded gasoline and gasoline blendstocks, diesel, kerosene, residual oil, and propane to home heating oil retailers and wholesale distributors. It also aggregates crude oil through truck or pipeline in the mid-continent region of the United States and Canada, as well as transports it through rail and ships it through barge to refiners. The company's Gasoline Distribution and Station Operations segment sells branded and unbranded gasoline to gasoline station operators and sub-jobbers; operates gasoline stations and convenience stores; and provides car wash, lottery, and ATM services, as well as leases gasoline stations. Its Commercial segment sells and delivers unbranded gasoline, home heating oil, diesel, kerosene, residual oil, and bunker fuel to customers in the public sector, as well as to commercial and industrial end-users; and sells custom blended fuels. As of December 31, 2021, the company had a portfolio of 1,595 owned, leased, and supplied gasoline stations, which included 295 directly operated convenience stores; and owned, leased, or maintained storage facilities at 26 bulk terminals with a collective storage capacity of 11.9 million barrels. Global GP LLC serves as the general partner of the company. The company was incorporated in 2005 and is based in Waltham, Massachusetts.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 16.49B | 18.88B | 13.25B | 8.32B | 13.08B | 12.67B | 8.92B | 8.24B | 10.31B | 17.27B | 19.59B | 17.63B | 14.84B | 7.80B | 5.82B | 9.02B | 6.76B | 4.47B | 1.25B | 3.19B | 2.48B | 1.59B | 1.75B |
Cost of Revenue | 15.98B | 17.78B | 12.53B | 7.60B | 12.42B | 12.02B | 8.34B | 7.69B | 9.72B | 16.73B | 19.18B | 17.29B | 14.63B | 7.63B | 5.67B | 8.90B | 6.63B | 4.36B | 1.22B | 3.11B | 2.41B | 1.54B | 1.69B |
Gross Profit | 513.83M | 1.10B | 719.26M | 721.14M | 662.76M | 650.41M | 583.05M | 546.49M | 597.67M | 542.61M | 405.83M | 333.49M | 209.60M | 166.72M | 149.83M | 119.79M | 126.98M | 113.23M | 28.91M | 75.87M | 67.10M | 55.20M | 62.50M |
Gross Profit Ratio | 3.12% | 5.81% | 5.43% | 8.67% | 5.07% | 5.13% | 6.54% | 6.63% | 5.79% | 3.14% | 2.07% | 1.89% | 1.41% | 2.14% | 2.58% | 1.33% | 1.88% | 2.53% | 2.31% | 2.38% | 2.71% | 3.46% | 3.56% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 273.73M | 263.11M | 212.88M | 192.53M | 170.94M | 171.00M | 155.03M | 149.67M | 177.04M | 153.96M | 115.49M | 101.46M | 152.14M | 113.84M | 96.09M | 73.85M | 73.24M | 65.19M | 15.44M | 53.04M | 30.30M | 27.50M | 26.80M |
Other Expenses | 0.00 | 454.12M | 364.29M | 334.14M | 353.81M | 279.45M | 309.05M | 297.94M | 303.81M | 222.94M | 204.93M | 147.44M | 4.80M | 3.53M | 2.99M | 2.88M | 2.25M | 1.53M | 390.00K | 4.79M | 18.80M | 17.70M | 0.00 |
Operating Expenses | 266.33M | 717.23M | 577.17M | 526.67M | 524.75M | 450.45M | 464.08M | 447.61M | 480.85M | 376.90M | 320.42M | 248.90M | 156.94M | 117.37M | 99.08M | 76.73M | 75.49M | 66.71M | 15.83M | 57.82M | 49.10M | 45.20M | 26.80M |
Cost & Expenses | 16.25B | 18.50B | 13.11B | 8.13B | 12.94B | 12.47B | 8.80B | 8.14B | 10.20B | 17.10B | 19.50B | 17.54B | 14.78B | 7.75B | 5.77B | 8.98B | 6.71B | 4.43B | 1.24B | 3.17B | 2.46B | 1.58B | 1.72B |
Interest Income | 0.00 | 81.26M | 80.09M | 83.54M | 89.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 85.63M | 81.26M | 80.09M | 83.54M | 89.86M | 89.15M | 86.23M | 86.32M | 73.33M | 47.76M | 43.54M | 36.27M | 31.21M | 22.31M | 15.19M | 20.80M | 17.41M | 11.90M | 2.69M | 4.70M | 2.00M | 2.20M | 3.00M |
Depreciation & Amortization | 110.09M | 104.80M | 102.24M | 100.14M | 108.19M | 106.84M | 105.65M | 111.94M | 13.50M | 18.87M | 19.22M | 45.46M | 30.36M | 20.08M | 2.99M | 15.13M | 9.61M | 4.11M | 953.00K | 3.23M | 0.00 | -1.10M | 26.07M |
EBITDA | 356.36M | 565.08M | 244.46M | 285.24M | 234.32M | 304.01M | 225.44M | -42.11M | 114.72M | 252.07M | 161.27M | 130.05M | 85.71M | 69.43M | 53.74M | 43.01M | 51.49M | 46.51M | 14.03M | 21.28M | 18.00M | 8.90M | 35.70M |
EBITDA Ratio | 2.16% | 2.06% | 1.15% | 2.47% | 1.14% | 1.66% | 1.44% | 1.31% | 1.26% | 1.07% | 0.53% | 0.74% | 0.56% | 0.89% | 0.92% | 0.65% | 0.70% | 1.12% | 1.12% | 0.67% | 0.73% | 0.56% | 2.04% |
Operating Income | 243.77M | 460.29M | 142.22M | 192.27M | 139.21M | 197.17M | 119.78M | -152.25M | 114.72M | 165.71M | 85.41M | 84.59M | 50.63M | 49.35M | 50.75M | 43.07M | 51.49M | 46.51M | 13.08M | 18.05M | 18.00M | 10.00M | 19.90M |
Operating Income Ratio | 1.48% | 2.44% | 1.07% | 2.31% | 1.06% | 1.56% | 1.34% | -1.85% | 1.11% | 0.96% | 0.44% | 0.48% | 0.34% | 0.63% | 0.87% | 0.48% | 0.76% | 1.04% | 1.05% | 0.57% | 0.73% | 0.63% | 1.13% |
Total Other Income/Expenses | -83.13M | -81.26M | -80.09M | -90.70M | -102.94M | -89.15M | -86.23M | -86.32M | -73.33M | -47.76M | -43.54M | -36.27M | -31.21M | -22.31M | -15.19M | -20.80M | -3.29M | -11.39M | 6.01M | 0.00 | -2.00M | -4.00M | 700.00K |
Income Before Tax | 160.64M | 379.03M | 62.13M | 101.56M | 36.27M | 108.03M | 33.55M | -238.57M | 41.39M | 117.94M | 41.87M | 48.32M | 19.42M | 27.04M | 35.56M | 22.21M | 48.20M | 35.13M | 10.39M | 0.00 | 16.00M | 6.00M | 20.60M |
Income Before Tax Ratio | 0.97% | 2.01% | 0.47% | 1.22% | 0.28% | 0.85% | 0.38% | -2.90% | 0.40% | 0.68% | 0.21% | 0.27% | 0.13% | 0.35% | 0.61% | 0.25% | 0.71% | 0.79% | 0.83% | 0.00% | 0.65% | 0.38% | 1.17% |
Income Tax Expense | 8.14M | 16.82M | 1.34M | -119.00K | 1.09M | 5.62M | -23.56M | 53.00K | -1.87M | 963.00K | 819.00K | 1.58M | 68.00K | 0.00 | 1.43M | 1.15M | 1.19M | 1.67M | 986.00K | 739.54K | 0.00 | 5.10M | -10.27M |
Net Income | 152.51M | 362.21M | 60.80M | 102.21M | 35.87M | 103.91M | 58.75M | -199.41M | 43.56M | 114.71M | 42.62M | 46.74M | 19.35M | 27.04M | 33.34M | 21.06M | 47.01M | 33.46M | 9.41M | 17.31M | 16.00M | 6.00M | 20.60M |
Net Income Ratio | 0.92% | 1.92% | 0.46% | 1.23% | 0.27% | 0.82% | 0.66% | -2.42% | 0.42% | 0.66% | 0.22% | 0.27% | 0.13% | 0.35% | 0.57% | 0.23% | 0.70% | 0.75% | 0.75% | 0.54% | 0.65% | 0.38% | 1.17% |
EPS | 3.77 | 10.06 | 1.79 | 2.77 | 0.82 | 3.08 | 1.74 | -5.95 | 1.12 | 3.97 | 1.43 | 1.73 | 0.88 | 1.61 | 2.56 | 1.57 | 1.38 | 2.46 | 1.60 | 3.07 | 2.84 | 1.06 | 3.65 |
EPS Diluted | 3.76 | 10.02 | 1.77 | 2.74 | 0.81 | 3.06 | 1.74 | -5.95 | 1.11 | 3.95 | 1.42 | 1.71 | 0.87 | 1.59 | 2.51 | 1.57 | 1.38 | 2.46 | 1.60 | 3.07 | 2.84 | 1.06 | 3.65 |
Weighted Avg Shares Out | 33.97M | 33.94M | 33.94M | 33.91M | 33.81M | 33.70M | 33.59M | 33.52M | 32.18M | 27.42M | 27.33M | 26.39M | 21.28M | 16.35M | 13.02M | 13.07M | 12.44M | 11.29M | 5.64M | 5.64M | 5.64M | 5.64M | 5.64M |
Weighted Avg Shares Out (Dil) | 34.04M | 34.04M | 34.28M | 34.31M | 34.34M | 33.97M | 33.63M | 33.53M | 32.32M | 27.50M | 27.56M | 26.57M | 21.47M | 16.60M | 13.28M | 13.07M | 12.44M | 11.29M | 5.64M | 5.64M | 5.64M | 5.64M | 5.64M |
First Results from Lexaria's Second GLP-1 Human Pilot Study
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
Hims & Hers Health: GLP-1 Is Not The Only Tailwind In This Growth Story
Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution
Defence Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
Source: https://incomestatements.info
Category: Stock Reports